Yuki Tsunoda was the highest-finishing driver to complete the 2024 Hungarian Grand Prix with a one-stop strategy. Tsunoda ...

The affected products were sold by retailers including Argos, B&M, DID, Lidl, Poundland, Robert Dyas, Tesco, and the Tower ...

The U.S. Food and Drug Administration has granted approval to Empaveli as the primary treatment for C3 glomerulopathy .The drug has received approval for patients over 12 years and above who work to ...

The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

This has led to strong growth for the company, with C3.ai's revenue rising 25% year over year in fourth-quarter fiscal year 2025 (ending April 30). It also expects strong growth for FY 2026, with ...

We've waited quite some time for a reasonable choice of affordable small electric cars, and while they’re not exactly coming ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

The full-season announcement, made in collaboration with the FIA and Formula 1, includes softer selections at Zandvoort and ...

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

This approval offers a promising new targeted treatment for patients aged 12 and older with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), ...

For three days inside the Charleston Convention Center, fire, EMS, law enforcement and dispatchers from the tri-county ...

Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet. Click here to read an analysis of APLS ...